Biological background {#s1}
=====================

Lymphocyte-associated gene 3 (LAG3) was identified in the 1990s as a novel transmembrane protein consisting of 489 amino acids with a structural homology to CD4, as both exhibit four extracellular domains.[@R1] Furthermore, the LAG3 gene is located close to the CD4 gene on chromosome 12. Despite these similarities on chromosomal localisation and similar intron/exon organisation, only approximately 20% of the amino acid sequences of these two molecules were identical. Structural properties were also similar with same extracellular folding patterns, which resulted in binding of LAG3 to major histocompatibility complex (MHC) class II as a ligand, even with an up to 100 times higher affinity than CD4.[@R2]

LAG3 is mainly expressed in activated T and natural killer (NK) cells and was identified to as a marker for the activation of CD4+ and CD8+ T cells.[@R5] Under pathological conditions, such as chronic inflammation or tumour environment, enhanced LAG3 expression on T cells was observed in combination with other inhibitory receptors such as programmed cell death receptor 1 (PD-1), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin-3 (TIM3), CD160, 2B4, which finally led to T cell dysfunction.[@R6] Furthermore, LAG3 was mainly found on tumour infiltrating regulatory T cells (Tregs) in many types of cancer when compared with non-malignant peripheral cells.[@R7]

Apart from immune and cancer cells, high LAG3 mRNA expression was commonly found in the red pulp of the spleen, thymic medulla and at the base of the cerebellum.[@R5]

Modulation of LAG3 expression and its cleavage from the cell surface is an obligatory process for optimal T cell function. Via this cleavage, soluble LAG3 (sLAG3) is released to the circulation, where so far no clear biological function has been identified.[@R8] Despite a lack of clinical evidence, detection of sLAG3 might serve as a prognostic biomarker in tuberculosis and as a diagnostic biomarker in type 1 diabetes.[@R10] From a clinical perspective, sLAG3 might provide information on the activation status of LAG3 and could be used as a biomarker in clinical studies testing new immunotherapies. Recently, patients with metastatic hormone-receptor positive breast cancer receiving immunotherapy had longer disease free and overall survival rates, when sLAG3 was detectable in serum.[@R12]

The co-expression of LAG3 with other inhibitory molecules including PD-1, TIGIT, TIM3, 2B4, CD160 induces the exhaustion of immune cells, which results in diminished cytokine secretion.[@R14] In line with these findings, the blockade of LAG3 on CD4 cells led to elevated production of interleukin (IL)-2, IL-4, interferon gamma and tumour necrosis factor alpha.[@R16] Earlier studies demonstrated little effect of LAG3 blockade on the resolution of T cell exhaustion, whereas dual LAG3/PD-1 blockade provided very significant results. Interestingly, both LAG3 and PD-1 deficient mice were usually capable to reduce large tumour volumes, whereas respective single knockouts showed only limited effects.[@R17] In line with this finding, in colon adenocarcinoma and fibrosarcoma tumour models, anti-PD-1 monotherapy revealed only limited benefits with a tumour clearance of 40% and 20%, respectively, whereas this increased to 80% and 70% when dual blockade with LAG3/PD-1 compounds was used.[@R17] Similar observations were reported in ovarian tumours,[@R19] melanomas,[@R20] lymphomas[@R19] and multiple myelomas.[@R21] As a hallmark of these in-vivo studies, increased survival and tumour clearance were mainly induced by repair of CD8+ T cell function and elevated cytokine production.

These highly significant in-vivo data demonstrate a clear synergy between LAG3 and PD-1 and accelerate the investigation of these inhibitory receptors on human samples and in further clinical trials as double blockade immunotherapies.

In humans, LAG3 was generally found to be co-expressed with PD-1, which together induced a T cell exhaustion state. Mainly, CD8+ positive tissue infiltrating lymphocytes isolated from patients with hepatocellular carcinoma, ovarian cancer and melanoma showed significant upregulation of LAG3 and high levels of PD-1.[@R22] MHC class II molecules, as ligands of LAG3, are expressed in a variety of cells and tumours such as melanomas.[@R26] LAG3 was frequently found to be ligated on MHC class II on melanoma cells, which lead to a clonal exhaustion of melanoma infiltrating T cells, thereby avoiding apoptosis.[@R27] In colorectal cancer, LAG3 was found at higher extent in microsatellite instability high tumours, which are known to be susceptible to immunotherapy.[@R28] Furthermore, LAG3 expression was found not only in tissue infiltrating lymphocytes but also in peripheral Tregs, tumour involved lymph nodes and within the tumour tissue itself, in melanoma and colon carcinoma.[@R29] In patients with head and neck squamous cell carcinoma and non-small cell lung cancer, LAG3 was expressed on tumour infiltrating Tregs.[@R30]

Targeted agents under development {#s2}
=================================

Targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and PD1/PD-L1 axis induced clinically relevant objective response rates and extended overall and progression free survival in patients with several different tumour types.[@R32] However, the majority of patients does not respond or develops a treatment resistance after responding to an immunotherapy.[@R34] Additionally, a significant increase of toxicity in patients receiving the dual treatment, particularly with CTLA4 inhibitors, became an important clinical problem.[@R36] Hence, there exists a clinical need for the identification of more inhibitory receptors, which might contribute to and increase the activity of the up to now identified immunotherapy components. Besides from approaches, which test combination of immunotherapy with chemotherapy, radiation therapy or cancer vaccines, novel combinations focus on the dual immune checkpoint blockade. In this regard, novel inhibitory molecules including LAG3 and TIM3 are gaining more importance as new targets.[@R15] The main goal of dual immunotherapy blockade should be the enhancement of the efficacy by extending progression free and overall survival without increasing the toxicity significantly.

The rationale of targeting LAG3 in addition to PD-1 and the strong preclinical data showing the efficacy of dual blockage of LAG3/PD-1 axis lead to the development of different drugs against the LAG3 molecule. First example was IMP321, which was designed to be a fusion recombinant protein having four extracellular domains like LAG3. This was followed by the development of monoclonal antibodies from various suppliers. Although these drugs are mainly used in clinical settings in combination with anti-PD-1 medication, some anti-LAG3 drugs were generated to be bispecific and target both LAG3 and PD-1, such as FS118 or dual affinity re-targeting protein MGD013.

These compounds, the mechanism of action and the producing company are summarised in [table 1](#T1){ref-type="table"}.

###### 

Compounds developed to target the LAG3 molecule in different biological structures

  Name of the compound     Mechanism of action                               Phase of clinical trial development   Company
  ------------------------ ------------------------------------------------- ------------------------------------- -------------------------
  IMP321                   APC activator                                     II                                    Prima BioMed/Immutep
  Relatlimab (BMS986016)   Fully human IgG4 mAb                              III                                   Bristol-Myers Squibb
  LAG525                   Fully human IgG4 mAb                              II                                    Novartis
  MK-4280                  Fully human IgG4 mAb                              I                                     Merck
  Sym-022                  Fully human Fc-inert mAb                          I                                     Symphogen
  TSR-033                  Fully human IgG4 mAb                              I                                     Tesaro
  REGN3767                 Fully human mAb                                   I                                     Regeneron Pharma/Sanofi
  MGD013                   DART protein binding both LAG3 and PD1            I                                     MacroGenics
  FS118                    Bispecific antibody binding both LAG3 and PD-L1   I                                     F-Star Delta
  INCAGN02385              Fc engineered IgG1k antibody                      I                                     Incyte Biosciences
  EOC202                   Human LAG-3 fusion protein                        I                                     EddingPharm Oncology

Only compounds, which entered clinical testing, are demonstrated in the table.

APC, antigen presenting cells; DART, dual affinity re-targeting; Ig, immunoglobulin; LAG3, lymphocyte-associated gene 3; PD-1, programmed death receptor 1; PD-L1, programmed death receptor ligand 1; mAb, monoclonal antibody.

Current ongoing clinical trials {#s3}
===============================

The early phase I dose escalation trials of IMP321 as a monotherapy performed at patients with metastatic renal cell carcinoma tested subcutaneous administration of doses raging between 0.05 mg and 30 mg.[@R38] This was safe and well tolerated. The response rates were however modest and mainly observed in patients with higher doses. This early trial demonstrated the rationale of combining the anti-LAG3 regimen with chemotherapy or other immunotherapies in order to increase the response and survival rates. Based on these results, two further trials in advanced pancreatic cancer and metastatic breast cancer in combination with chemotherapy were designed. Within the first trial, IMP321 was combined with gemcitabine in patients with advanced pancreatic cancer.[@R39] The efficacy and immunomodulation was insufficient that the authors recommended using higher doses of treatment in further trials. Within the second phase I trial, patients with metastatic breast cancer were treated with IMP321 in combination with paclitaxel in a first-line setting.[@R40] Patients received different doses of IMP321 via subcutaneous injection every 2 weeks for 6 months. Toxicity was acceptable; there was a significant durable response with enhanced clinical outcome when compared with historical controls. The data of this trial lead to conduction of the placebo-controlled randomised phase II trial, where IMP321 was tested together with paclitaxel in patients with metastatic hormone receptor positive breast cancer. The preliminary efficacy data was demonstrated at American Society of Clinical Oncology (ASCO) congress in 2018.[@R41] Here, a biweekly dose of 30 mg was recommended for further testing of the phase II trial, since this dose was shown to be the most effective with the least toxicity. IMP321 led to a steady and enhanced antigen-presenting cells (APC) and T cell activation. Within the same congress, the same dosage of IMP321 was demonstrated to be safe in combination with pembrolizumab in patients with melanoma who had a progressive disease after immunotherapy.[@R42]

BMS-986016 (relatlimab) was the first anti-LAG3 mAb to be developed and is currently being evaluated in various clinical trials including solid tumours as well as haematological malignancies. The initial phase I/IIa trial of relatlimab sought to investigate the efficacy of the drug alone or in combination with nivolumab in patients with advanced diseases. The preliminary data of this trial investigating relatlimab and nivolumab in patients with melanoma who progressed after immunotherapy were demonstrated at ASCO congress in 2017.[@R43] The efficacy was encouraging with an acceptable safety profile. At the time of the congress report, 31 patients had evaluable results with an ORR of 16% and DOR of 45%.

Further concepts of clinical trials testing other anti-LAG3 regimen were introduced at the latest large oncological congresses, and the data is expected to be published within the next few years. [Table 2](#T2){ref-type="table"} summarises the ongoing clinical trials of various anti-LAG3 drugs in different settings. So far, relatlimab represents the only drug, which reached a phase III trial testing and several phase II approaches. Some other drugs including MK-4280, Sym022, TSR-033, REGN3767, MGD013, FS118, INCAGN02385 and EOC202 are in early phase I testing.

###### 

Current ongoing clinical trials investigating anti-LAG3 drugs in various solid tumours and haematological malignancies as of December 2018

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ClinicalTrials.gov identifier (or other database)   Tumour type                                              Setting (early or advanced disease, first, second or more lines if mts)   Phase    Treatment arms                                                           Target accrual
  --------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------- -------- ------------------------------------------------------------------------ ----------------
  NCT03252938                                         Advanced solid tumours                                   Second line                                                               I        IMP321 (injection directly into the tumour)                              38

  NCT03625323                                         Advanced NSCLC\                                          First line or immunotherapy refractory\                                   II       IMP321+pembrolizumab                                                     120
                                                      Advanced HNSCC                                           Second line                                                                                                                                                 

  NCT02614833                                         Met breast cancer, HR positive                           First line                                                                II       IMP321                                                                   241

  NCT02658981                                         Glioblastoma                                             Second line                                                               I        Relatlimab±nivolumab                                                     260

  NCT02061761                                         B-Cell malignancies                                      Relapsed or refractory                                                    I/IIa    Relatlimab±nivolumab                                                     132

  NCT01968109                                         Advanced solid tumours                                   Second line (melanoma and NSCLC cohorts first line)                       I/IIa    Relatlimab±nivolumab                                                     1000

  NCT03610711                                         Advanced gastro-oesophageal tumours                      Second line                                                               I        Relatlimab+nivolumab+RTX                                                 15

  NCT03044613                                         Oesophagus and GEJ, stage II/III                         First line                                                                I        Relatlimab+nivolumab+RTX                                                 32

  NCT02966548                                         Advanced solid tumours                                   Second line                                                               I        Relatlimab±nivolumab                                                     45

  NCT03662659                                         Advanced gastric or GEJ                                  First line                                                                II       Relatlimab+nivolumab                                                     250

  NCT03459222                                         Advanced solid tumours                                   First line                                                                I/II     Relatlimab+nivolumab+ IDO inhibitor or relatlimab+nivolumab+ipilimumab   230

  NCT03607890                                         MSI-H solid tumours                                      Refractory to previous PD-(L)1 Treatment                                  II       Relatlimab+nivolumab                                                     21

  NCT02519322                                         Resectable stage IIIB/IV Melanomas                       First line, peri-Operative                                                II       Relatlimab+nivolumab                                                     53

  NCT02060188                                         MSI-H and non MSI advanced colorectal cancer             First and further line                                                    II       Relatlimab+Nivolumab                                                     340

  NCT03470922                                         Advanced melanoma                                        First line                                                                II/III   Relatlimab                                                               700

  NCT03642067                                         MSS stable advanced colorectal carcinomas                Second and further line                                                   II       Relatlimab+nivolumab                                                     64

  NCT02460224                                         Advanced solid tumours                                   Second line                                                               I/II     LAG525±PDR001                                                            515

  NCT03365791                                         Advanced solid tumours and haematological malignancies   Second and further line                                                   II       LAG525+PDR001                                                            160

  NCT02720068                                         Advanced solid tumours                                   Salvage setting                                                           I        MK-4280±pembrolizumab                                                    408

  NCT03489369                                         Advanced solid tumours or lymphomas                      Second line or where no standard treatment available                      I        Sym022                                                                   30

  NCT03250832                                         Advanced solid tumours                                   Second line                                                               I        TSR-033±anti-PD-1                                                        260

  NCT03005782                                         Advanced solid tumours and lymphomas                     Second line                                                               I        REGN3767±REGN2810                                                        546

  NCT03219268                                         Advanced solid tumours and haematological malignancies   Second line                                                               I        MGD013                                                                   243

  NCT03440437                                         Advanced solid tumours and haematological malignancies   After PD-1/PD-L1 blockage                                                 I        FS118                                                                    51

  NCT03538028                                         Advanced solid tumours and lymphomas                     Salvage setting                                                           I        INCAGN02385                                                              55

  NCT03600090                                         Metastatic breast cancer                                 First line                                                                I        EOC202+CHT                                                               18
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CHT, chemotherapy; GEJ, gastro-oesophageal junction; HNSCC, squamous head and neck cancer; HR, hormone receptor; IDO, indoleamine (2,3)-dioxygenase; LAG3, lymphocyte-assoiated gene 3; MSI-H, microsatellite instability high; NSCLC, non-small cell lung cancer; PD-1, programmed death receptor 1; PD-L1, programmed death receptor ligand 1; RTX, radiation therapy.

Conclusions {#s4}
===========

Due to the success gained by the dual blockage of CTLA4 and PD-(L)1, new approaches for single immunotherapies, which might enhance their efficacy are established. In the last few years, LAG3 has gained widespread interest as an inhibitory receptor. Its synergistic biology with PD-1 provided a reasonable rationale to combine this molecule with anti-PD-1 agents. There are currently 11 molecules, which target LAG3 and are already being tested in clinical trials. The results of the early clinical trials demonstrate modest benefit of single anti-LAG3 treatment, which again supports potential combination approaches with other inhibitory receptors.

There are still many unanswered questions regarding the LAG3 biology including its exact function and the existence of ligands other than the MHC class II. Until now, LAG3 has mainly been combined with the PD-(L)1 axis in clinical trials. If a combination with other inhibitory molecules is feasible or not still remains unclear. The clinical implications of LAG3 as a biomarker is also a less reported issue. Whether circulating soluble LAG3 or tissue expression of LAG3 could be used as biomarkers in the course of immunotherapy is now one of the questions, which hopefully will be answered in large clinical trials. Nevertheless, apart from the lack of knowledge on its function and its effector cells, preliminary data, which has been demonstrated so far by phase I trials and congress reports, shows promising and durable response rates with acceptable toxicity, making this molecule a focus of intensive research.
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